These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24943989)

  • 21. N-terminal pyroglutamate formation in CX3CL1 is essential for its full biologic activity.
    Kehlen A; Haegele M; Böhme L; Cynis H; Hoffmann T; Demuth HU
    Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28739588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Developmental expression and subcellular localization of glutaminyl cyclase in mouse brain.
    Hartlage-Rübsamen M; Staffa K; Waniek A; Wermann M; Hoffmann T; Cynis H; Schilling S; Demuth HU; Rossner S
    Int J Dev Neurosci; 2009 Dec; 27(8):825-35. PubMed ID: 19699792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of thyrotropin-releasing hormone as hippocampal glutaminyl cyclase substrate in neurons and reactive astrocytes.
    Waniek A; Hartlage-Rübsamen M; Höfling C; Kehlen A; Schilling S; Demuth HU; Roßner S
    Biochim Biophys Acta; 2015 Jan; 1852(1):146-55. PubMed ID: 25446989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors.
    Xu C; Wang YN; Wu H
    J Med Chem; 2021 May; 64(10):6549-6565. PubMed ID: 34000808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A pathogenic mechanism of N-terminally pyroglutamylated Aβ and possible application of Alzheimer's disease by inhibition of the pyroglutamylation].
    Iwata N; Asai M
    Rinsho Shinkeigaku; 2012; 52(11):1162-4. PubMed ID: 23196550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease.
    Hartlage-Rübsamen M; Waniek A; Meissner J; Morawski M; Schilling S; Jäger C; Kleinschmidt M; Cynis H; Kehlen A; Arendt T; Demuth HU; Rossner S
    Acta Neuropathol; 2015 Apr; 129(4):565-83. PubMed ID: 25666182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disturbed Ca2+ homeostasis increases glutaminyl cyclase expression; connecting two early pathogenic events in Alzheimer's disease in vitro.
    De Kimpe L; Bennis A; Zwart R; van Haastert ES; Hoozemans JJ; Scheper W
    PLoS One; 2012; 7(9):e44674. PubMed ID: 22970285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients.
    Bridel C; Hoffmann T; Meyer A; Durieux S; Koel-Simmelink MA; Orth M; Scheltens P; Lues I; Teunissen CE
    Alzheimers Res Ther; 2017 Jun; 9(1):38. PubMed ID: 28587659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An overview of glutaminyl cyclase inhibitors for Alzheimer's disease.
    Coimbra JR; Sobral PJ; Santos AE; Moreira PI; Salvador JA
    Future Med Chem; 2019 Dec; 11(24):3179-3194. PubMed ID: 31838899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IsoQC (QPCTL) knock-out mice suggest differential substrate conversion by glutaminyl cyclase isoenzymes.
    Becker A; Eichentopf R; Sedlmeier R; Waniek A; Cynis H; Koch B; Stephan A; Bäuscher C; Kohlmann S; Hoffmann T; Kehlen A; Berg S; Freyse EJ; Osmand A; Plank AC; Roßner S; von Hörsten S; Graubner S; Demuth HU; Schilling S
    Biol Chem; 2016 Jan; 397(1):45-55. PubMed ID: 26351917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
    Schilling S; Zeitschel U; Hoffmann T; Heiser U; Francke M; Kehlen A; Holzer M; Hutter-Paier B; Prokesch M; Windisch M; Jagla W; Schlenzig D; Lindner C; Rudolph T; Reuter G; Cynis H; Montag D; Demuth HU; Rossner S
    Nat Med; 2008 Oct; 14(10):1106-11. PubMed ID: 18836460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice.
    Hoffmann T; Rahfeld JU; Schenk M; Ponath F; Makioka K; Hutter-Paier B; Lues I; Lemere CA; Schilling S
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides.
    Schlenzig D; Manhart S; Cinar Y; Kleinschmidt M; Hause G; Willbold D; Funke SA; Schilling S; Demuth HU
    Biochemistry; 2009 Jul; 48(29):7072-8. PubMed ID: 19518051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glutaminyl cyclases, the potential targets of cancer and neurodegenerative diseases.
    Zhang Y; Wang Y; Zhao Z; Peng W; Wang P; Xu X; Zhao C
    Eur J Pharmacol; 2022 Sep; 931():175178. PubMed ID: 35948163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-Terminal pyroglutamate formation of Aβ38 and Aβ40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation.
    Schlenzig D; Rönicke R; Cynis H; Ludwig HH; Scheel E; Reymann K; Saido T; Hause G; Schilling S; Demuth HU
    J Neurochem; 2012 Jun; 121(5):774-84. PubMed ID: 22375951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of Glutaminyl Cyclase Genes Involved in Pyroglutamate Modification of Fungal Lignocellulolytic Enzymes.
    Wu VW; Dana CM; Iavarone AT; Clark DS; Glass NL
    mBio; 2017 Jan; 8(1):. PubMed ID: 28096492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice.
    Crehan H; Liu B; Kleinschmidt M; Rahfeld JU; Le KX; Caldarone BJ; Frost JL; Hettmann T; Hutter-Paier B; O'Nuallain B; Park MA; DiCarli MF; Lues I; Schilling S; Lemere CA
    Alzheimers Res Ther; 2020 Jan; 12(1):12. PubMed ID: 31931873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased glutaminyl cyclase activity in brains of Alzheimer's disease individuals.
    Gunn AP; Wong BX; McLean C; Fowler C; Barnard PJ; Duce JA; Roberts BR;
    J Neurochem; 2021 Mar; 156(6):979-987. PubMed ID: 32614980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphate ions and glutaminyl cyclases catalyze the cyclization of glutaminyl residues by facilitating synchronized proton transfers.
    Seifert F; Demuth HU; Weichler T; Ludwig HH; Tittmann K; Schilling S
    Bioorg Chem; 2015 Jun; 60():98-101. PubMed ID: 25981125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glutaminyl cyclase knock-out mice exhibit slight hypothyroidism but no hypogonadism: implications for enzyme function and drug development.
    Schilling S; Kohlmann S; Bäuscher C; Sedlmeier R; Koch B; Eichentopf R; Becker A; Cynis H; Hoffmann T; Berg S; Freyse EJ; von Hörsten S; Rossner S; Graubner S; Demuth HU
    J Biol Chem; 2011 Apr; 286(16):14199-208. PubMed ID: 21330373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.